MRRSE announces addition of new report "Global Market Study on Active Pharmaceutical Ingredient (API): Synthetic Chemical API Segment Is Estimated to Account for More Than 60% Share of the Market by 2015 End in Terms Of Revenue" to its database

Albany, NY -- (SBWire) -- 01/09/2017 --The global Active Pharmaceutical Ingredient (API) market is valued at US$ 127 Bn in 2014 and it is projected to expand at a healthy CAGR during the forecast period.

By API types, the biological API market segment is expected to have the highest growth rate of around 8% during the forecast period of 2015-2020. The biological API segment is valued at about 30% of the global API market in 2014. It grew at an year on year growth rate of about 8% during 2015.

Request a Sample Copy of the Report @ http://www.mrrse.com/sample/2295

The global API market is transforming, as large pharmaceutical companies shift focus toward the biological APIs segment. Over 100 different biologic therapeutic agents have been approved for use in the U.S. and several more are awaiting marketing approval. The companies that used to rely solely on small molecules (synthetic chemical API) for their revenue are now considering new avenues to maintain the revenue stream due to generic influx. Protein-based therapeutics (peptides, proteins, enzymes and antibodies) have emerged as a major growth engine in the biological API market. Large pharmaceutical companies are scaling down their small molecule manufacturing facilities to focus on biologic drugs, thereby presenting greater opportunities for contract manufacturing companies. The overall cost of drug development program for biologics is less as compared to chemical APIs, primarily because of high success rates in the pipeline phase. This factor has attracted higher investments in the biologics and biosimilars market.

Inquiry on this report @ http://www.mrrse.com/enquiry/2295

Apart from the currently marketed blockbuster biologics such as Humira and Herceptin, several other promising biologics such as mepolizumab (GSK), dupilumab (Sanofi/Regeron), alirocumab (Sanofi), evolocumab (Amgen), brodalumab (Amgen), ixekizumab (Eli Lilly) and secukinumab (Novartis) are expected to enter different geographical markets during the forecast period from 2015 to 2020. Presently, most of the biologics are manufactured in-house due to intellectual property concerns and quality issues. However, the manufacturing of biological APIs is a very complex and challenging process. Hence, innovator companies are outsourcing to contract manufacturing companies with biological production expertise.

Read Complete Report with TOC @ http://www.mrrse.com/active-pharmaceutical-ingredient-market

Teva Pharmaceutical Industries Ltd dominated active pharmaceutical ingredients market in 2014. Major factors attributed to its dominance are broad product portfolio and high market penetration. Zhejiang Medicine Co., Ltd. and Zhejiang NHU Co., Ltd secured the second market position in 2015. North China Pharmaceutical Group Corp. (NCPC) and Northeast Pharmaceutical Group Co., Ltd. held the third position in 2015. Other players in the active pharmaceutical ingredients market include Dr.Reddy\'s Laboratories Limited, Sandoz (Novartis AG), Aurobindo Pharma Limited, Zhejiang Hisun Pharmaceutical Co., Ltd. and Zhejiang Huahai Pharmaceuticals Co., Ltd. and others

About MRRSE
MRRSE stands for Market Research Reports Search Engine, the largest online catalog of latest market research reports based on industries, companies, and countries. MRRSE sources thousands of industry reports, market statistics, and company profiles from trusted entities and makes them available at a click. Besides well-known private publishers, the reports featured on MRRSE typically come from national statistics agencies, investment agencies, leading media houses, trade unions, governments, and embassies.